Cabaletta Bio (CABA) Expected to Announce Earnings on Wednesday

Cabaletta Bio (NASDAQ:CABA - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its earnings results on Wednesday, May 21st. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.04). On average, analysts expect Cabaletta Bio to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cabaletta Bio Trading Up 12.2%

NASDAQ CABA traded up $0.22 on Friday, reaching $2.03. The company's stock had a trading volume of 15,811,946 shares, compared to its average volume of 1,539,137. The firm has a market cap of $103.01 million, a PE ratio of -0.94 and a beta of 2.72. The business has a 50-day moving average price of $1.36 and a 200 day moving average price of $2.24. Cabaletta Bio has a 52 week low of $0.99 and a 52 week high of $13.50.

Institutional Trading of Cabaletta Bio

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC bought a new stake in shares of Cabaletta Bio during the first quarter valued at approximately $102,000. Comerica Bank grew its stake in shares of Cabaletta Bio by 2,292.1% during the first quarter. Comerica Bank now owns 41,599 shares of the company's stock valued at $58,000 after purchasing an additional 39,860 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Cabaletta Bio by 357.1% during the first quarter. Invesco Ltd. now owns 61,675 shares of the company's stock valued at $85,000 after purchasing an additional 48,181 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CABA shares. Morgan Stanley lowered their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and issued a $25.00 target price on shares of Cabaletta Bio in a research note on Tuesday, April 1st. Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 1st. Guggenheim upped their price objective on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, UBS Group decreased their price objective on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $20.33.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.